Mobble
Health · Cancer research · published 2026-08-14 · via STAT News

Bristol's new myeloma drug wins FDA approval, opening a new treatment category

The FDA has approved a Bristol Myers Squibb treatment for advanced multiple myeloma, making it the first in a new class of drugs for this blood cancer. The oral therapy offers a new option for patients with the disease.

Read the full article at STAT News →
Related stories
Today's pharma briefing: Legal clash over drug testing and a new cancer therapy · Cancer research
FDA grants accelerated approval to Bristol Myers Squibb's iberdomide for relapsed multiple myeloma · Cancer research
Biogen's felzartamab gains first regulatory nod in China for multiple myeloma · Drug development
Ultragenyx wins first FDA nod for gene therapy targeting rare metabolic disease · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class.” Browse more stories.